Madrigal Pharmaceuticals, Inc.

MDGL

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Resmetirom	Phase 3	NASH	-
Placebo	Phase 3	Non-Alcoholic Fatty Liver Disease	-
MGL-3196	Phase 2	Heterozygous Familial Hypercholesterolemia	-

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

March 2026~Resmetirom

Primary completion for Resmetirom trial (NCT04951219) in Non-Alcoholic Fatty Liver Disease

Regulatory Approvals

MDGL News